These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19689226)

  • 21. Novel potent agonist [(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor.
    Peng YL; Chang M; Dong SL; Li W; Han RW; Fu GX; Chen Q; Wang R
    Regul Pept; 2006 May; 134(2-3):75-81. PubMed ID: 16516988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
    Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids.
    Arduin M; Spagnolo B; Calò G; Guerrini R; Carrà G; Fischetti C; Trapella C; Marzola E; McDonald J; Lambert DG; Regoli D; Salvadori S
    Bioorg Med Chem; 2007 Jul; 15(13):4434-43. PubMed ID: 17490886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol.
    Bojnik E; Babos F; Fischetti C; Magyar A; Camarda V; Borsodi A; Bajusz S; Calo' G; Benyhe S
    Brain Res Bull; 2010 Mar; 81(4-5):477-83. PubMed ID: 19800951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nociceptin antagonism: probing the receptor by N-acetyl oligopeptides.
    Kocsis L; Orosz G; Magyar A; Al-Khrasani M; Kató E; Rónai AZ; Bes B; Meunier JC; Gündüz O; Tóth G; Borsodi A; Benyhe S
    Regul Pept; 2004 Nov; 122(3):199-207. PubMed ID: 15491792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity.
    Kapusta DR; Thorkildsen C; Kenigs VA; Meier E; Vinge MM; Quist C; Petersen JS
    J Pharmacol Exp Ther; 2005 Aug; 314(2):652-60. PubMed ID: 15855355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist.
    Salvadori S; Guerrini R; Calo G; Regoli D
    Farmaco; 1999; 54(11-12):810-25. PubMed ID: 10668183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol.
    Gündüz O; Rizzi A; Baldisserotto A; Guerrini R; Spagnolo B; Gavioli EC; Kocsis L; Magyar A; Benyhe S; Borsodi A; Calò G
    Eur J Pharmacol; 2006 Jun; 539(1-2):39-48. PubMed ID: 16682024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological activity of new series of N-modified analogues of the N/OFQ(1-13)NH2 with aminophosphonate moiety.
    Todorov PT; Mateeva PI; Zamfirova RN; Pavlov ND; Naydenova ED
    Amino Acids; 2012 Sep; 43(3):1217-23. PubMed ID: 22143428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.
    Chiou LC; Liao YY; Fan PC; Kuo PH; Wang CH; Riemer C; Prinssen EP
    Curr Drug Targets; 2007 Jan; 8(1):117-35. PubMed ID: 17266536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex.
    Mela F; Marti M; Ulazzi L; Vaccari E; Zucchini S; Trapella C; Salvadori S; Beani L; Bianchi C; Morari M
    Eur J Neurosci; 2004 Mar; 19(5):1317-24. PubMed ID: 15016089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation.
    Nishimura H; Li J; Isozaki K; Okada K; Matsushima A; Nose T; Costa T; Shimohigashi Y
    Bioorg Med Chem; 2009 Aug; 17(15):5683-7. PubMed ID: 19577933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.
    McDonald J; Calo G; Guerrini R; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):183-7. PubMed ID: 12595960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of activity for nociceptin in the mouse vas deferens.
    Berzetei-Gurske IP; Schwartz RW; Toll L
    Eur J Pharmacol; 1996 Apr; 302(1-3):R1-2. PubMed ID: 8791013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The nociceptin receptor antagonist [Nphe1,Arg14,Lys15]nociceptin/orphanin FQ-NH2 blocks the stimulatory effects of nociceptin/orphanin FQ on the HPA axis in rats.
    Leggett JD; Harbuz MS; Jessop DS; Fulford AJ
    Neuroscience; 2006 Sep; 141(4):2051-7. PubMed ID: 16784820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.
    Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y
    Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ-RYYRIK hybrid peptides.
    Erdei AI; Borbély A; Magyar A; Szűcs E; Ötvös F; Gombos D; Al-Khrasani M; Stefanucci A; Dimmito MP; Luisi G; Mollica A; Benyhe S
    Peptides; 2019 Feb; 112():106-113. PubMed ID: 30513351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist.
    Calo' G; Guerrini R; Bigoni R; Rizzi A; Marzola G; Okawa H; Bianchi C; Lambert DG; Salvadori S; Regoli D
    Br J Pharmacol; 2000 Mar; 129(6):1183-93. PubMed ID: 10725267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception.
    Lohman RJ; Harrison RS; Ruiz-Gómez G; Hoang HN; Shepherd NE; Chow S; Hill TA; Madala PK; Fairlie DP
    Vitam Horm; 2015; 97():1-55. PubMed ID: 25677767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Receptor binding properties and antinociceptive effects of chimeric peptides consisting of a micro-opioid receptor agonist and an ORL1 receptor antagonist.
    Kawano S; Ito R; Nishiyama M; Kubo M; Matsushima T; Minamisawa M; Ambo A; Sasaki Y
    Biol Pharm Bull; 2007 Jul; 30(7):1260-4. PubMed ID: 17603164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.